



## **Deciphera Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call and Webcast on March 9, 2020**

March 2, 2020

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it will report its fourth quarter and full year 2019 financial results on Monday, March 9, 2020.

In connection with the earnings release, Deciphera's management team will host a live conference call and webcast at 4:30 PM ET on Monday, March 9, 2020, to discuss the Company's financial results and provide a general corporate update.

The conference call may be accessed by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) and referring to conference ID 1669368. A webcast of the conference call will be available in the "Events and Presentations" page in the "Investors" section of the Company's website at <https://investors.deciphera.com/news-events/events-presentations>. The archived webcast will be available on the Company's website approximately two hours after the conference call and will be available for 30 days following the call.

### **About Deciphera Pharmaceuticals**

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule product candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a "switched off" or inactivated conformation. These investigational therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, and agents designed to inhibit reprogramming of cancer cell metabolism. We have used our platform to develop a diverse pipeline of tumor-targeted, immuno-targeted, and metabolism-targeted product candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their responses to treatment.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200302005108/en/): <https://www.businesswire.com/news/home/20200302005108/en/>

#### Investor Relations:

Jen Robinson  
Deciphera Pharmaceuticals, Inc.  
[jrobinson@deciphera.com](mailto:jrobinson@deciphera.com)  
781-906-1112

#### Media:

David Rosen  
Argot Partners  
[David.Rosen@argotpartners.com](mailto:David.Rosen@argotpartners.com)  
212-600-1902

Source: Deciphera Pharmaceuticals, Inc.